A Pill for Sleep Apnea? What Zepbound's Approval Means for CPAP Users

On 16 June 2026, Health Canada approved Zepbound (tirzepatide) as the country's first-ever medication for obstructive sleep apnea (OSA) — but only for adults who are also living with obesity. For the millions of people who manage their apnea every night with a CPAP machine, it's the headline that prompts the obvious question: is there finally a pill instead of the mask? The short answer is no — not for most people, and not yet here in Australia.

What happened

According to Eli Lilly Canada and reporting from CTV News, Health Canada cleared Zepbound for the treatment of moderate to severe OSA in adults with obesity (a BMI of 30 kg/m² or greater), used alongside a reduced-calorie diet and increased physical activity. It's a once-weekly injection — the same active ingredient (tirzepatide) already used for weight management — not a tablet and not a quick fix.

The approval rests on the SURMOUNT-OSA trial. As summarised in Eli Lilly's release, the results split into two groups:

Among people unwilling or unable to use PAP therapy: Zepbound delivered around 25 fewer breathing interruptions per hour (versus 5 on placebo), and 42% reached remission or mild, non-symptomatic OSA (versus 16% on placebo).
Among people already using PAP therapy: about 29 fewer interruptions per hour (versus 6 on placebo), with 50% reaching remission or mild OSA (versus 14%).

Importantly, this is a Canadian approval. It is not a Therapeutic Goods Administration (TGA) decision, so it does not change what's available in Australia today.

Why it matters

For years, the story of sleep apnea treatment has been dominated by airway pressure — CPAP, APAP and BiPAP. A drug that meaningfully lowers the apnea-hypopnea index by treating the underlying obesity is a genuinely new lever, and it reflects how tightly weight and OSA are bound together. As Dr R.J. Kamatovic described it, the medication targets a "self-perpetuating cycle" in which disrupted sleep worsens metabolic health, which in turn worsens sleep.

But notice the fine print. The approval is specifically for people with obesity, the trial pairs the drug with diet and exercise, and even in the best-performing group, half of patients did not reach remission. This is an additional tool for a specific group — not a replacement for therapy that works for everyone with OSA, including people at a healthy weight.

What this means for Australian CPAP users

If you're an Australian managing sleep apnea, here's the practical read:

Your CPAP is still the gold standard. CPAP works the night you start it, regardless of your weight, and it's the most established treatment for OSA. Nothing about this approval changes that.
It's not available here as an OSA treatment. This is a Health Canada approval. Any decision about a sleep apnea indication in Australia would sit with the TGA — so talk to your GP or sleep physician rather than acting on overseas headlines.
Weight and apnea travel together. Even setting medications aside, the trial is a reminder that managing weight can improve OSA severity. That's a conversation worth having with your clinician alongside your therapy — not instead of it.
Adherence still wins. A drug that takes months to work won't protect your sleep tonight. A well-fitted mask and a machine you actually use will.

"42% achieved remission or mild, non-symptomatic OSA" among trial patients unwilling or unable to use PAP therapy — Eli Lilly Canada, citing the SURMOUNT-OSA trial.

The bottom line

Zepbound's Canadian approval is a real milestone — the first time a medication has been cleared specifically for obstructive sleep apnea in that market — and it points to a future where OSA is treated from more than one angle. But for the vast majority of CPAP users, and for everyone in Australia right now, the machine on your bedside table remains the proven path to a quieter, safer night's sleep. If you're curious about what newer treatments might mean for you, the best next step is a chat with your sleep specialist — and in the meantime, keep that mask on.